Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: QT Prolongation Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

NCT02441829
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Diltiazem in Jervell and Lange-Nielsen Syndrome

NCT06534671
View directory record Official record
Conditions
Jervell and Lange Nielsen Syndrome
Interventions
diltiazem
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

KCNQ1 Cascade Screening

NCT03783975
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Simplified Cascade Screening
Genetic
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

NCT03258515
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD6094 200 mg, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

NCT02300558
View directory record Official record
Conditions
Long QT Syndrome Type 3
Interventions
Eleclazine, Eleclazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

NCT01648205
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Placebo, Ranolazine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 20, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional

Continuous Versus Intermittent cARdiac Electrical moNitorinG

NCT04336644
View directory record Official record
Conditions
Torsades de Pointe Caused by Drug, Long QT Syndrome
Interventions
BodyGuardian Mini Plus
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational

Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center

NCT02898337
View directory record Official record
Conditions
QT Interval Prolongation
Interventions
AliveCor handheld mobile ECG
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional

Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome

NCT00839501
View directory record Official record
Conditions
Andersen-Tawil Syndrome
Interventions
Potassium, Acetazolamide
Dietary Supplement · Drug
Lead sponsor
University of Rochester
Other
Eligibility
10 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational

The Effect of General Anesthesia on the Risk for Arrhythmia

NCT01174251
View directory record Official record
Conditions
Arrhythmia
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 20, 2026, 4:04 AM EDT
Active, not recruiting No phase listed Observational

Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3

NCT07075445
View directory record Official record
Conditions
Long QT Syndrome Type 3, Long QT Syndrome 2
Interventions
Not listed
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CAEB071 Thorough QTc Study in Healthy Volunteers

NCT01594255
View directory record Official record
Conditions
Healthy
Interventions
sotrastaurin, placebo to sotrastaurin, Avelox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

NCT00926263
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CP-751,871, CP-751,871, moxifloxacin, saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 20, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional

Comparing Direct vs Indirect Methods for Cascade Screening

NCT05348564
View directory record Official record
Conditions
Long QT Syndrome, Familial Hypercholesterolemia, Ethics, Genetic Testing
Interventions
Direct contact of family members for cascade screening of relevant variants
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Methadone Pharmacokinetics and Cardiac Effects in Newborns

NCT00715988
View directory record Official record
Conditions
Pain
Interventions
Methadone HCl Inject 10 mg/ml (will require dilution), Methadone
Drug
Lead sponsor
University of Utah
Other
Eligibility
29 Weeks to 48 Weeks
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 20, 2026, 4:04 AM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

NCT07277582
View directory record Official record
Conditions
Long QT Syndrome (LQTS) 2
Interventions
baseline lead-in, THRV-1268
Other · Drug
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

NCT02412098
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational

Long QT Syndrome-Population Genetics and Cardiac Studies

NCT00005176
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Ventricular Arrhythmia, Long QT Syndrome
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Up to 100 Years
Enrollment
2,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 20, 2026, 4:04 AM EDT
Not yet recruiting No phase listed Observational

MCG In Long QT Syndrome

NCT07270211
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Magnetocardiography
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide, Testosterone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

NCT02365506
View directory record Official record
Conditions
LQT2 Syndrome
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational

Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

NCT01705925
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Not listed
Lead sponsor
Pediatrix
Other
Eligibility
Up to 20 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrophysiological Effects of Potential QT Prolonging Drugs

NCT05716854
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 20, 2026, 4:04 AM EDT